Skip to content

The efficacy and safety of remifentanil in sedation of patients undergoing transesophageal echocardiography: a prospective, clinically controlled study

The efficacy and safety of remifentanil in sedation of patients undergoing transesophageal echocardiography: a prospective, clinically controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096830
Enrollment
Unknown
Registered
2025-02-07
Start date
2025-02-10
Completion date
Unknown
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal ultrasound

Interventions

Rimazolen group:Sedation with remifentanil combined with fentanyl and maintained until the end of the examination
Dexmedetomidine group:Sedation with dexmedetomidine combined with fentanyl and maintenance until the end of the examination

Sponsors

The First People's Hospital of Neijiang City, Sichuan Province
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years old; 2.ASA: Level II-III; 3.Admitted to the cardiology department of our hospital, transesophageal echocardiography measurement is required before the planned left atrial appendage occlusion surgery; 4.Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe arrhythmia, such as resting HR = 450 ms, female >= 470ms; 2. Acute heart failure, unstable angina, myocardial infarction in the last 6 months; Current presence of heart failure (NYHAIII and IV) or severe valvular heart disease; 3.Poorly controlled hypertension (sitting systolic blood pressure (SBP) >= 160 mmHg and/or sitting diastolic blood pressure (DBP) >=100 mmHg) on antihypertensive medications); 4. Sitting systolic blood pressure <= 90 mmHg; 5.Suffering from psychiatric illness, long-term use of psychotropic medications, or cognitive dysfunction; 6. Known contraindications to benzodiazepines, dexmedetomidine; 7. Pregnant or planning to become pregnant; 8.Other situations that are considered inappropriate by the researcher to participate in the project.

Design outcomes

Primary

MeasureTime frame
Sedation success rate;

Secondary

MeasureTime frame
Sedation onset time;Number and incidence of body movements during operation;Anesthesia maintenance BIS value80 duration;Wake-up time;bradycardia;hypotension;hypoxemia;Postoperative nausea and vomiting incidence rate;Pharyngeal pain rating;

Countries

China

Contacts

Public ContactZhang Yue

The First People's Hospital of Neijiang City

464266456@qq.com+86 152 8327 4393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026